Cancer Biology & Medicine最新文献_第6页

Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing prospective phase II study. 术中使用低能x射线源放射治疗可切除胰腺癌的安全性和有效性：一项正在进行的前瞻性II期研究的中期评估。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2025-01-03 DOI: 10.20892/j.issn.2095-3941.2024.0287

Xingyun Chen, Shuo Li, Chuntao Gao, Wei Wang, Haorui Li, Yuxiao Liu, Rui Liu, Jihui Hao

{"title":"Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing prospective phase II study.","authors":"Xingyun Chen, Shuo Li, Chuntao Gao, Wei Wang, Haorui Li, Yuxiao Liu, Rui Liu, Jihui Hao","doi":"10.20892/j.issn.2095-3941.2024.0287","DOIUrl":"10.20892/j.issn.2095-3941.2024.0287","url":null,"abstract":"Objective: The role of intraoperative radiation therapy (IORT) in the management of resectable pancreatic cancer (RPC) remains unclear. To date, the application of IORT using a low-energy X-ray source has not been extensively investigated. Therefore, this study was conducted to evaluate the safety and efficacy of IORT using a 50 kV X-ray source in treating RPC.Methods: Patients with RPC who underwent radical pancreatectomy and IORT were enrolled. The primary endpoint was time to treatment failure (TTF) survival, whereas the secondary endpoints were safety and overall survival (OS).Results: By November 2023, 35 patients with RPC were treated according to the study protocol. The median TTF was 11.67 months, whereas the median OS for the cohort was 22.2 months. The local recurrence rate was 20%. The most common postoperative complication was pancreatic fistula. The incidence of delayed gastric emptying was 20%. Within 30 days after surgery, one patient experienced abdominal pain, another experienced vomiting, and one died because of abdominal infection and a grade C pancreatic fistula. Carcinoembryonic antigen (CEA) and D-dimer levels significantly correlated with TTF and OS in multivariate analyses. The carbohydrate antigen 19-9 (CA19-9) level was another prognostic factor significantly associated with OS. Patients with low D-dimer and normal CA19-9 levels showed prolonged OS with an IORT dose ≤ 15 Gy.Conclusions: This study supports use of IORT with a 50 kV X-ray source in treating RPC. IORT using a low-energy X-ray source was well-tolerated and feasible. Additionally, D-dimer, CEA, and CA19-9 levels may help identify patient profiles potentially benefitting from IORT.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects. 晚期神经内分泌肿瘤的治疗策略：现状与展望。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2025-01-03 DOI: 10.20892/j.issn.2095-3941.2024.0507

Sisi Ye, Juan Li, Jianming Xu

引用次数: 0

Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization. 推进精准医疗：人工智能在免疫基因组学、放射组学和病理学中对生物标志物发现和免疫治疗优化的变革作用。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2025-01-02 DOI: 10.20892/j.issn.2095-3941.2024.0376

Luchen Chang, Jiamei Liu, Jialin Zhu, Shuyue Guo, Yao Wang, Zhiwei Zhou, Xi Wei

{"title":"Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization.","authors":"Luchen Chang, Jiamei Liu, Jialin Zhu, Shuyue Guo, Yao Wang, Zhiwei Zhou, Xi Wei","doi":"10.20892/j.issn.2095-3941.2024.0376","DOIUrl":"10.20892/j.issn.2095-3941.2024.0376","url":null,"abstract":"Artificial intelligence (AI) is significantly advancing precision medicine, particularly in the fields of immunogenomics, radiomics, and pathomics. In immunogenomics, AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease prognosis, thus providing strong support for personalized treatments. In radiomics, AI can analyze high-dimensional features from computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) images to discover imaging biomarkers associated with tumor heterogeneity, treatment response, and disease progression, thereby enabling non-invasive, real-time assessments for personalized therapy. Pathomics leverages AI for deep analysis of digital pathology images, and can uncover subtle changes in tissue microenvironments, cellular characteristics, and morphological features, and offer unique insights into immunotherapy response prediction and biomarker discovery. These AI-driven technologies not only enhance the speed, accuracy, and robustness of biomarker discovery but also significantly improve the precision, personalization, and effectiveness of clinical treatments, and are driving a shift from empirical to precision medicine. Despite challenges such as data quality, model interpretability, integration of multi-modal data, and privacy protection, the ongoing advancements in AI, coupled with interdisciplinary collaboration, are poised to further enhance AI's roles in biomarker discovery and immunotherapy response prediction. These improvements are expected to lead to more accurate, personalized treatment strategies and ultimately better patient outcomes, marking a significant step forward in the evolution of precision medicine.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the lysine lactylome for the treatment of glioma. 靶向赖氨酸乳酸酶治疗胶质瘤。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-30 DOI: 10.20892/j.issn.2095-3941.2024.0461

Di Wang, Guanzhang Li, Tao Jiang, Wei Zhang

引用次数: 0

Multifaceted efforts of governments, medical institutions, and financial organizations contribute to reducing the health inequality caused by economic differences. 政府、医疗机构和金融组织多方面的努力有助于减少经济差异造成的健康不平等。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-30 DOI: 10.20892/j.issn.2095-3941.2024.0402

Fangshi Xu, Hangyu Fu, Jiancang Ma

引用次数: 0

Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma. 免疫抑制剂对肿瘤肺转移的影响：肝细胞癌移植的新见解。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-24 DOI: 10.20892/j.issn.2095-3941.2024.0267

Jinyan Chen, Huigang Li, Jianyong Zhuo, Zuyuan Lin, Zhihang Hu, Chiyu He, Xiang Wu, Yiru Jin, Zhanyi Lin, Renyi Su, Yiyang Sun, Rongsen Wang, Jiancai Sun, Xuyong Wei, Shusen Zheng, Di Lu, Xiao Xu

{"title":"Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.","authors":"Jinyan Chen, Huigang Li, Jianyong Zhuo, Zuyuan Lin, Zhihang Hu, Chiyu He, Xiang Wu, Yiru Jin, Zhanyi Lin, Renyi Su, Yiyang Sun, Rongsen Wang, Jiancai Sun, Xuyong Wei, Shusen Zheng, Di Lu, Xiao Xu","doi":"10.20892/j.issn.2095-3941.2024.0267","DOIUrl":"10.20892/j.issn.2095-3941.2024.0267","url":null,"abstract":"Pulmonary metastasis is a life-threatening complication for patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). In addition to the common mechanisms underlying tumor metastasis, another inevitable factor is that the application of immunosuppressive agents, including calcineurin inhibitors (CNIs) and rapamycin inhibitors (mTORis), after transplantation could influence tumor recurrence and metastasis. In recent years, several studies have reported that mTORis, unlike CNIs, have the capacity to modulate the tumorigenic landscape post-liver transplantation by targeting metastasis-initiating cells and reshaping the pulmonary microenvironment. Therefore, we focused on the effects of immunosuppressive agents on the lung metastatic microenvironment and how mTORis impact tumor growth in distant organs. This revelation has provided profound insights into transplant oncology, leading to a renewed understanding of the use of immunosuppressants after LT for HCC.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 11","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents. 促黄体激素释放激素受体激动剂和拮抗剂在前列腺癌中的作用：对长期生存的影响以及与下一代激素药物的联合治疗。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-24 DOI: 10.20892/j.issn.2095-3941.2024.0139

Jinge Zhao, Junru Chen, Guangxi Sun, Pengfei Shen, Hao Zeng

{"title":"Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.","authors":"Jinge Zhao, Junru Chen, Guangxi Sun, Pengfei Shen, Hao Zeng","doi":"10.20892/j.issn.2095-3941.2024.0139","DOIUrl":"10.20892/j.issn.2095-3941.2024.0139","url":null,"abstract":"Prostate cancer is a leading cause of cancer-related death in men worldwide. Luteinizing hormone-releasing hormone receptor (LHRH-R) agonists and antagonists are known to achieve castration-level testosterone suppression; however, long-term data comparing the survival benefits of these therapies are insufficient to inform treatment decisions. Furthermore, the advent of next-generation hormonal agents (NHAs), such as abiraterone and enzalutamide, have shifted the paradigm of managing prostate cancer. Although LHRH-R agonists and antagonists remain the cornerstone treatment across various stages of prostate cancer, they are increasingly administered with NHAs, because the combination treatment confers a survival advantage. Nevertheless, the differences in efficacy and safety profiles among various combinations of LHRH-R agonists and antagonists and NHAs remain unclear. Hence, this narrative review is aimed at providing a comprehensive overview of the long-term outcomes of various LHRH-R agonists and antagonists. Key data from major clinical studies are summarized, categorized by disease stage. LHRH-R agonists and antagonists, particularly goserelin, have demonstrated long-term survival benefits in patients with localized and locally advanced prostate cancer. The clinical outcomes of different LHRH-R agonists and antagonists in combination with NHAs have also been evaluated. Among the various combinations, goserelin plus abiraterone appears to have a manageable safety profile with relatively low rates of hot flushes and fatigue. Overall, long-term survival data and safety profiles should be considered in selecting optimal combination therapies for prostate cancer treatment.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 11","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity. 阐明CD4+ T和树突状细胞在抗肿瘤免疫中的协同作用。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-11 DOI: 10.20892/j.issn.2095-3941.2024.0453

Xiubao Ren

引用次数: 0

Deciphering the cell surface glyco-code: a promising perspective on unveiling the vulnerability of cancer stem cells. 解读细胞表面糖密码：揭示癌症干细胞脆弱性的一个有希望的视角。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-11 DOI: 10.20892/j.issn.2095-3941.2024.0408

Yuanyan Wei, Anning Wei, Yirong Li, Yuerong Yang, Yu Si, Yi Li, Zhijun Fan, Jianhai Jiang

引用次数: 0

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages. 奥西替尼通过激活巨噬细胞中的IL-6/JAK/STAT3通路，加剧免疫检查点抑制剂相关的严重不良事件。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-12-09 DOI: 10.20892/j.issn.2095-3941.2024.0269

Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren

{"title":"Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.","authors":"Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren","doi":"10.20892/j.issn.2095-3941.2024.0269","DOIUrl":"10.20892/j.issn.2095-3941.2024.0269","url":null,"abstract":"Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). However, the mechanisms underlying macrophages in irAEs have not been elucidated.Methods: An osimertinib and ICI-induced irAE mouse model was constructed. Lung micro-CT scans were used to assess the degree of inflammatory infiltration. Hematoxylin-eosin staining was used to analyze the histopathologic inflammatory infiltration in mouse liver and lung tissues. Flow cytometry was used to detect the percentages of T cells, NK cells, and macrophages and the expression of EGFR. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum interleukin (IL)-6, alanine transaminase (ALT), ferritin, and tumor necrosis factor (TNF)-α levels. Total RNA extracted from mouse liver macrophages was analyzed by RNA-seq. Simple Western blot analysis was used to detect the IL-6/JAK/STAT3 pathway activation state.Results: Osimertinib combined with ICIs upregulated EGFR expression on macrophages with increased serum IL-6, ALT, and ferritin levels. RNA-seq and simple Western blot analysis of mouse liver macrophages confirmed that that the IL-6/JAK/STAT3 pathway was activated in the combination treatment group. Ruxolitinib blocked the IL-6/JAK/STAT3 pathway and significantly decreased the serum IL-6, ALT, and ferritin levels in the combination treatment group.Conclusions: An osimertinib and ICI-induced irAE mouse model was constructed that showed osimertinib combined with ICIs inhibited EGFR phosphorylation and activated the IL-6/JAK/STAT3 signaling pathway in mouse liver macrophages, which led to the release of relevant cytokines.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0